Skip to content

The Function of Nutrition Rich Vegan Drink on Inflammatory Bowel Disease

The Function of Nutrition Rich Vegan Drink on Inflammatory Bowel Disease

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04297852
Enrollment
50
Registered
2020-03-06
Start date
2020-03-03
Completion date
2022-12-01
Last updated
2022-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recovery

Brief summary

The aim of this project, would be to develop a new formula, with high nutrition content on a vegan basis. The investigators expect to produce this novel vegan-based juice product, which does not exist on the marked today. The juice would consist of different selected varieties of vegetables and fruits. Beside the vegetables, the juice will also contain plant oils to increase the calorie level, as well as a protein sources containing amino acids with high anabolic effects. The products will be tested in an intervention study on patients with inflammatory bowel disease.

Interventions

DIETARY_SUPPLEMENTVegan drink

Vegan based drink containing vegetables, fruits and plant oils. Dose: 500 mL a day

DIETARY_SUPPLEMENTControl

Placebo drink Dose: 500 mL a day

Sponsors

Future Food Innovation
CollaboratorINDUSTRY
Per Bendix Jeppesen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Between 18 and 85 years old * Diagnosed with or show signs of UC or Crohns disease * Mild symptoms i.e intestinal symptoms * Has had the same medicin the previous week before starting in the study

Exclusion criteria

* Food or vegetable allergi * Cognitive diseases e.g alzheimers or dementia * Has diabetes requiring insulin or GLP-1 analog treatment (NB: No does include T2D patients, taking tablets or other diabetes therapy)

Design outcomes

Primary

MeasureTime frameDescription
Inflammatory factors3 weeksF-calprotectin

Countries

Denmark

Contacts

Primary ContactPer B Jeppesen, Prof
per.bendix.jeppesen@clin.au.dk28151877

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026